Featured Research

from universities, journals, and other organizations

Combating Age-related Immune-response Decline: Protein Found To Stimulate Production Of T-cells

Date:
July 23, 2008
Source:
University of Montreal
Summary:
Scientists have identified a protein that stimulates the production of T-cells, the white blood cells involved in the recognition and the elimination of infectious agents. The discovery could help to combat age-related declines in immune response.

A team of Canadian and Finnish scientists has identified a protein able to stimulate the production of T-cells, the white blood cells involved in the recognition and the elimination of infectious agents. The discovery by researchers of the Institute for Research in Immunology and Cancer (IRIC) at the Universitι de Montrιal in Canada and the University of Oulu in Finland could help to combat age-related declines in immune response.

Thanks to the work of Dr. Claude Perreault and his team, which identified the properties of a protein called Wnt4, it is now possible to envision news ways to reverse the age-related decline of the immune system. "Thymic atrophy is a major public health problem," said Dr. Perreault.

"It compromises the efficacy of vaccination and weakens the resistance to common viruses, for instance to the respiratory syncytial virus (RSV), which is responsible each year for the hospitalization of more than 150,000 people in the U.S. This is due to the fact that 'old' T cells are not equipped to face the threat of new foreign bodies, whether they are viruses or tumours."

The atrophy of the thymus, a small gland at the base of the neck where T cells mature, is one of the most obvious signs of the age-related decline of the immune system. This decline becomes significant towards the age of 50. It is caused not only by a decreased output of T cells from the thymus, but also by a decreased ability to recognize new antigens. The result is an increased susceptibility to infection as well as a lowered resistance to the immunosuppressive effects of chemotherapy.

Wnt4 protein stimulates white blood cells

By inducing an overproduction of the Wnt4 protein in the cells of the mouse immune system, Dr. Perreault and his collaborators were able to observe the stimulatory effect this protein exerts on the development of white blood cells. Using molecular markers that are specific to the different stages of cell maturation, IRIC researchers determined that elevated levels of Wnt4 led to a marked increase in the number of white blood cell progenitors, and of immature T cells in the thymus in particular.

Conversely, they found that deletion of the Wnt4 gene and lack of the corresponding protein was associated with a decrease in the number of T cell progenitors in the thymus.

After showing that Wnt4 could stimulate thymopoiesis, the name given to the production of T cells in the thymus, Dr. Perreault and his team sought to understand the mode of action of the protein. Isabelle Louis, a graduate student, and Dr. Krista Heinonen, a postdoctoral fellow, analyzed the changes in gene activity triggered by exposure to

Wnt4. Results were conclusive: Wnt4 increases the number of T cell progenitors by inducing the expression of genes involved in cell survival. IRIC researchers also showed that Wnt4 does not mediate these changes in gene expression through the intracellular pathway normally activated by members of the Wnt family, i.e. stabilization of a signalling protein called b-catenin, but rather through an alternative pathway involving members of the JNK family of proteins. The IRIC team is now investigating ways to capitalize on its discovery to develop new therapeutic agents.

The research was funded by the Canadian Institutes of Health Research and the National Cancer Institute of Canada.


Story Source:

The above story is based on materials provided by University of Montreal. Note: Materials may be edited for content and length.


Journal Reference:

  1. Louis et al. The Signaling Protein Wnt4 Enhances Thymopoiesis and Expands Multipotent Hematopoietic Progenitors through β-Catenin-Independent Signaling. Immunity, 2008; 29 (1): 57 DOI: 10.1016/j.immuni.2008.04.023

Cite This Page:

University of Montreal. "Combating Age-related Immune-response Decline: Protein Found To Stimulate Production Of T-cells." ScienceDaily. ScienceDaily, 23 July 2008. <www.sciencedaily.com/releases/2008/07/080722114201.htm>.
University of Montreal. (2008, July 23). Combating Age-related Immune-response Decline: Protein Found To Stimulate Production Of T-cells. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/07/080722114201.htm
University of Montreal. "Combating Age-related Immune-response Decline: Protein Found To Stimulate Production Of T-cells." ScienceDaily. www.sciencedaily.com/releases/2008/07/080722114201.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins